首页> 外文期刊>International journal of biological sciences >Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells
【24h】

Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells

机译:抑制己糖激酶II介导的糖酵解有助于非小细胞肺癌细胞中哌隆定诱导的肿瘤抑制。

获取原文
           

摘要

Deregulation of glycolysis is a common phenomenon in human non-small cell lung cancer (NSCLC). In the present study, we reported the natural compound, piperlongumine, has a profound anti-tumor effect on NSCLC via regulation of glycolysis. Piperlongumine suppressed the proliferation, colony formation and HK2-mediated glycolysis in NSCLC cells. We demonstrated that exposure to piperlongumine disrupted the interaction between HK2 and VDAC1, induced the activation of the intrinsic apoptosis signaling pathway. Moreover, our results revealed that piperlongumine down-regulated the Akt signaling, exogenous overexpression of constitutively activated Akt1 in HCC827 and H1975 cells significantly rescued piperlongumine-induced glycolysis suppression and apoptosis. The xenograft mouse model data demonstrated the pivotal role of suppression of Akt activation and HK2-mediated glycolysis in mediating the in vivo antitumor effects of piperlongumine. The expression of HK2 was higher in malignant NSCLC tissues than that of the paired adjacent tissues, and was positively correlated with poor survival time. Our results suggest that HK2 could be used as a potential predictor of survival and targeting HK2 appears to be a new approach for clinical NSCLC prevention or treatment.
机译:糖酵解失调是人类非小细胞肺癌(NSCLC)的普遍现象。在本研究中,我们报道了天然化合物pipelongongine通过调节糖酵解对NSCLC具有深远的抗肿瘤作用。哌隆定抑制了NSCLC细胞的增殖,集落形成和HK2介导的糖酵解。我们证明,暴露于哌隆定会破坏HK2和VDAC1之间的相互作用,诱导内在凋亡信号通路的激活。此外,我们的研究结果表明,哌隆君碱下调了Akt信号传导,HCC827和H1975细胞中组成型激活Akt1的外源性过表达显着挽救了哌隆君碱诱导的糖酵解抑制和细胞凋亡。异种移植小鼠模型数据证明抑制Akt激活和HK2介导的糖酵解在介导哌隆金胺的体内抗肿瘤作用中起着关键作用。恶性NSCLC组织中HK2的表达高于配对的邻近组织,并且与不良的生存时间呈正相关。我们的结果表明,HK2可以用作潜在的生存预测指标,而靶向HK2似乎是临床NSCLC预防或治疗的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号